These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 14500173)

  • 1. Cefepime versus cefpirome: the importance of creatinine clearance.
    Lipman J; Wallis SC; Boots RJ
    Anesth Analg; 2003 Oct; 97(4):1149-1154. PubMed ID: 14500173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance.
    Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cefepime in patients with thermal burn injury.
    Bonapace CR; White RL; Friedrich LV; Norcross ED; Bosso JA
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2848-54. PubMed ID: 10582870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing.
    Lipman J; Wallis SC; Rickard CM; Fraenkel D
    Intensive Care Med; 2001 Feb; 27(2):363-70. PubMed ID: 11396280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.
    Burgess DS; Hastings RW; Hardin TC
    Clin Ther; 2000 Jan; 22(1):66-75. PubMed ID: 10688391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables.
    Georges B; Conil JM; Seguin T; Dieye E; Cougot P; Decun JF; Lavit M; Samii K; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2008 Apr; 46(4):157-64. PubMed ID: 18397688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefpirome clinical pharmacokinetics.
    Strenkoski LC; Nix DE
    Clin Pharmacokinet; 1993 Oct; 25(4):263-73. PubMed ID: 8261711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval.
    Banyai M; Thalhammer F; El-Menyawi I; Heinz G; Traunmüller F; Siostrzonek P
    Clin Pharmacol Ther; 2000 Apr; 67(4):368-72. PubMed ID: 10801245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function.
    Tam VH; McKinnon PS; Akins RL; Drusano GL; Rybak MJ
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1853-61. PubMed ID: 12760858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.
    Malone RS; Fish DN; Abraham E; Teitelbaum I
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3148-55. PubMed ID: 11600370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model].
    Elkhaïli H; Pompei D; Peter JD; Linger L; Salmon J; Levêque D; Niedergang S; Salmon Y; Thierry RC; Monteil H; Jehl F
    Pathol Biol (Paris); 1997 May; 45(5):347-56. PubMed ID: 9296083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment.
    Jungheinrich C; Scharpf R; Wargenau M; Bepperling F; Baron JF
    Anesth Analg; 2002 Sep; 95(3):544-51, table of contents. PubMed ID: 12198032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study.
    Huwyler T; Lenggenhager L; Abbas M; Ing Lorenzini K; Hughes S; Huttner B; Karmime A; Uçkay I; von Dach E; Lescuyer P; Harbarth S; Huttner A
    Clin Microbiol Infect; 2017 Jul; 23(7):454-459. PubMed ID: 28111294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
    Kays MB
    Pharmacotherapy; 1999 Dec; 19(12):1392-9. PubMed ID: 10600088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia.
    Aitken SL; Altshuler J; Guervil DJ; Hirsch EB; Ostrosky-Zeichner LL; Ericsson CD; Tam VH
    Int J Antimicrob Agents; 2015 May; 45(5):541-4. PubMed ID: 25665726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of cefepime in the neonate.
    Capparelli E; Hochwald C; Rasmussen M; Parham A; Bradley J; Moya F
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2760-6. PubMed ID: 15980347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the pharmacokinetics of cefpirome sulphate in the elderly.
    Sugihara H; Narita N; Takatsu R; Horiuchi M; Yonenami K; Hotta M; Shibahara K; Kamo T; Negishi Y
    J Clin Pharm Ther; 1998 Oct; 23(5):375-9. PubMed ID: 9875686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective monitoring of cefepime in intensive care unit adult patients.
    Chapuis TM; Giannoni E; Majcherczyk PA; Chioléro R; Schaller MD; Berger MM; Bolay S; Décosterd LA; Bugnon D; Moreillon P
    Crit Care; 2010; 14(2):R51. PubMed ID: 20359352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics, safety, and tolerance of cefepime administered as an intravenous bolus or as a rapid infusion.
    Garrelts JC; Wagner DJ
    Ann Pharmacother; 1999 Dec; 33(12):1258-61. PubMed ID: 10630824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.